NCT03874247 is a Phase 3 clinical trial of pelubiprofen 45mg in Acute Traumatic Injury, sponsored by Daewon Pharmaceutical Co., Ltd..

Who is sponsoring NCT03874247?

NCT03874247 is sponsored by Daewon Pharmaceutical Co., Ltd..

What drugs are being tested in NCT03874247?

Interventions in NCT03874247: pelubiprofen 45mg, pelubiprofen placebo.

What condition does NCT03874247 study?

NCT03874247 studies Acute Traumatic Injury.

Is NCT03874247 still recruiting?

NCT03874247 is currently status unknown. Last updated 19 March 2019.

Last reviewed 2019-03-19 · How we verify

NCT03874247

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Trial to Evaluate the Efficacy and Safety of 'Pelubiprofen Controlled Released Tab.' in Acute Traumatic Injury

Status unknown Phase 3 Last updated 19 March 2019

What this trial tests

Phase 3 trial testing pelubiprofen 45mg in Acute Traumatic Injury in 94 participants. Status unknown.

Timeline

25 February 2019

Primary endpoint
31 December 2019

31 December 2019

Quick facts

Lead sponsor	Daewon Pharmaceutical Co., Ltd.
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	94
Start date	25 February 2019
Primary completion	31 December 2019
Estimated completion	31 December 2019
Sites	1 location across South Korea

Drugs / interventions tested

pelubiprofen 45mg — full drug profile →
pelubiprofen placebo — full drug profile →

Conditions studied

Acute Traumatic Injury — all drugs for Acute Traumatic Injury →

Sponsor

Daewon Pharmaceutical Co., Ltd. — full company profile →

Who can join

19 and older, any sex, with Acute Traumatic Injury. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A randomized, double-blind, placebo-controlled, parallel, multi-center phase III clinical trial

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Daewon Pharmaceutical Co., Ltd. trials

Trials by the same sponsor.

NCT07364851 — A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetics of DW4421-T1 and DW4421S-T1 in Healthy Adult Volunt · Phase 1 · not yet recruiting
NCT07349589 — Evaluate the Safety, Tolerability and Pharmacokinetics of DW5524 in Healthy Adult Volunteers · Phase 1 · not yet recruiting
NCT07364877 — A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetics of DW4421 and DW4421S in Healthy Adult Volunteers · Phase 1 · enrolling by invitation
NCT07343245 — A Phase 1 Clinical Trial to Evaluate the Safety and DDI of DW4421 and 3 NSAIDs · Phase 1 · recruiting
NCT07319559 — Clinical Trial to Evaluate the Safety, Pharmacokinetic Characteristics of DW5124 and DW5124-R, and the Effect of Food on · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03874247 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Daewon Pharmaceutical Co., Ltd.
Last refreshed: 19 March 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03874247.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing